Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Infante

Showing results (231-240 of 299) with videos related to

Pageof 30
Sort By:
Investigational New Drugs|August 7, 2019
Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanomaShahneen Sandhu, Catriona M McNeil, Patricia LoRusso, et al.
Cancer Chemotherapy and Pharmacology|July 8, 2010
Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumorsE Claire Dees, Jeffrey R Infante, Roger B Cohen, et al.
Investigational New Drugs|August 22, 2014
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinomaNizar M Tannir, Andres Forero-Torres, Radhakrishnan Ramchandren, et al.
International Journal of Nanomedicine|February 25, 2015
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumorsHuali Wu, Jeffrey R Infante, Vicki L Keedy, et al.
British Journal of Clinical Pharmacology|December 16, 2017
Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumoursNoelia Nebot, Hendrik-Tobias Arkenau, Jeffrey R Infante, et al.
European Journal of Cancer (Oxford, England : 1990)|April 16, 2013
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumoursJeffrey R Infante, Kyriakos P Papadopoulos, Johanna C Bendell, et al.
Revista Espanola De Medicina Nuclear|December 18, 2009
[Optimization of sentinel lymph node biopsy in breast cancer by intraoperative axillary palpation]J Serrano Vicente, J R Infante de la Torre, M L Domínguez Grande, et al.
Biomed Research International|August 23, 2014
Accumulation of extracellular hyaluronan by hyaluronan synthase 3 promotes tumor growth and modulates the pancreatic cancer microenvironmentAnne Kultti, Chunmei Zhao, Netai C Singha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2021
A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid TumorsJames J Harding, Melinda Telli, Pamela Munster, et al.
Investigational New Drugs|September 4, 2015
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumorsSuzanne F Jones, Lillian L Siu, Johanna C Bendell, et al.
Pageof 30

Showing results (231-240 of 299) with videos related to

Sort By:
Pageof 30
Investigational New Drugs|August 7, 2019
Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanomaShahneen Sandhu, Catriona M McNeil, Patricia LoRusso, et al.
Cancer Chemotherapy and Pharmacology|July 8, 2010
Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumorsE Claire Dees, Jeffrey R Infante, Roger B Cohen, et al.
Investigational New Drugs|August 22, 2014
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinomaNizar M Tannir, Andres Forero-Torres, Radhakrishnan Ramchandren, et al.
International Journal of Nanomedicine|February 25, 2015
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumorsHuali Wu, Jeffrey R Infante, Vicki L Keedy, et al.
British Journal of Clinical Pharmacology|December 16, 2017
Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumoursNoelia Nebot, Hendrik-Tobias Arkenau, Jeffrey R Infante, et al.
European Journal of Cancer (Oxford, England : 1990)|April 16, 2013
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumoursJeffrey R Infante, Kyriakos P Papadopoulos, Johanna C Bendell, et al.
Revista Espanola De Medicina Nuclear|December 18, 2009
[Optimization of sentinel lymph node biopsy in breast cancer by intraoperative axillary palpation]J Serrano Vicente, J R Infante de la Torre, M L Domínguez Grande, et al.
Biomed Research International|August 23, 2014
Accumulation of extracellular hyaluronan by hyaluronan synthase 3 promotes tumor growth and modulates the pancreatic cancer microenvironmentAnne Kultti, Chunmei Zhao, Netai C Singha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2021
A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid TumorsJames J Harding, Melinda Telli, Pamela Munster, et al.
Investigational New Drugs|September 4, 2015
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumorsSuzanne F Jones, Lillian L Siu, Johanna C Bendell, et al.
Pageof 30